Sugi Predict

Sugi Predict / Compounds / SCHEMBL2218360

SCHEMBL2218360

SCHEMBL2218360

CN1CCN(C(=O)Nc2cncc(Br)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.51
▸ ALDH1A1 P00352 4/20 0.48
▸ MAPT P10636 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ LMNA P02545 2/20 0.44
▸ DUSP3 P51452 1/20 0.44
▸ PTPN5 P54829 1/20 0.44
▸ PTPN11 Q06124 1/20 0.44
▸ APOBEC3G Q9HC16 1/20 0.44
▸ RAB9A P51151 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ PANK3 Q9H999 2/20 0.43
▸ FAAH O00519 1/20 0.42
▸ ALPL P05186 1/20 0.42
▸ CCR2 P41597 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ HTR1D P28221 1/20 0.41
▸ HTR1B P28222 1/20 0.41
▸ HTR2A P28223 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4306485 0.83 KDM4E (0.58) KDM4EALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL12397622 0.83 SMN1; SMN2 (0.54) KDM4EALDH1A1MAPTSMN1; SMN2RAB9A
SCHEMBL12515437 0.83 KDM4E (0.51) KDM4EALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL24568835 0.79 TERT (0.57) ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL4307557 0.78 KDM4E (0.52) KDM4EALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL4310718 0.78 KDM4E (0.68) KDM4EALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL2268552 0.78 DYRK1A (0.52) KDM4EMAPT
SCHEMBL15134852 0.77 RAB9A (0.71) KDM4EALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL2376190 0.75 L3MBTL1 (0.60) KDM4EALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL13621144 0.74 KDM4E (0.67) KDM4EALDH1A1MAPTSMN1; SMN2FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3305073-B1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED LLC (US) 2019-05-15 — — EP disclosed
EP-3305073-B1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED LLC (US) 2019-05-15 — — EP disclosed
US-10105370-B2 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2018-10-23 — — US disclosed
US-20180256588-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-09-13 — — US disclosed
EP-3305073-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF Samumed, LLC (US) 2018-04-11 — — EP disclosed
EP-3305073-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF Samumed, LLC (US) 2018-04-11 — — EP disclosed
US-9855272-B2 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2018-01-02 — — US disclosed
EP-3001903-B1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED LLC (US) 2017-10-25 — — EP disclosed
EP-3001903-B1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED LLC (US) 2017-10-25 — — EP disclosed
US-20170202846-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2017-07-20 — — US disclosed
US-20130296307-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2013-11-07 — — US disclosed
US-20130225576-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2013-08-29 — — US disclosed
US-20130225576-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2013-08-29 — — US disclosed
US-8450340-B2 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2013-05-28 — — US disclosed
US-8450340-B2 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2013-05-28 — — US disclosed
CN-102821607-A 1H-pyrazolo [3,4-b ] pyridines and therapeutic uses thereof SAMUMED LLC 2012-12-12 — — CN disclosed
EP-2515655-A1 1H-PYRAZOLO[3,4-BETA]PYRIDINES AND THERAPEUTIC USES THEREOF Samumed, LLC (US) 2012-10-31 — — EP disclosed
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-08-04 — — US disclosed
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-08-04 — — US disclosed
WO-2011084486-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF BRCA1, THPO, PDXK KDM4E 1972/4885ALDH1A1 123/4885MAPT 2756/4885
US-20130225576-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF BRCA1, THPO, PDXK KDM4E 1972/4885ALDH1A1 123/4885MAPT 2756/4885
US-20170202846-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF BRCA1, THPO, PDXK KDM4E 1972/4885ALDH1A1 123/4885MAPT 2756/4885
US-10105370-B2 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof BRCA1, THPO, PDXK KDM4E 1972/4885ALDH1A1 123/4885MAPT 2756/4885
US-20180256588-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF BRCA1, THPO, PDXK KDM4E 1972/4885ALDH1A1 123/4885MAPT 2756/4885
US-20130296307-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF BRCA1, THPO, PDXK KDM4E 1972/4885ALDH1A1 123/4885MAPT 2756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.